- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2015
- Public Summary Document (PSD) November 2015 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2015 PBAC Meeting - Word
Blinatumomab – November 2015
Blinatumomab: powder for IV infusion, 38.5 µg, Blincyto®
Last updated
18 April 2016